The broader medication supply picture has, on the most rigorous tracking data the FDA publishes, stabilised meaningfully over the past two years after the persistent shortages of the early 2020s. Several specific categories remain in shortage, however, with consequences for the patients who depend on the affected medications and limited operational options for the broader healthcare system.

What remains short

The remaining shortage categories are concentrated in older generic injectable medications, in specific chemotherapy drugs, and in a small number of contrast media used in diagnostic imaging. The categories share certain characteristics: production economics that do not strongly motivate suppliers to expand capacity, manufacturing complexity that limits the supplier base to a small number of operators, and demand patterns that are difficult to forecast.

The structural reasons

The structural reasons for the persistent shortages have been well-mapped. Generic injectable medications often operate at production margins so thin that any single supplier disruption produces market-wide effects; the supplier base for many such medications has consolidated to two or three global producers.

The federal policy response has produced incremental improvements. Federal incentive programmes for additional manufacturing capacity have enrolled several producers; the Strategic National Stockpile has been expanded for some categories. Neither change has fully closed the structural gap.

What patients can do

For patients in the affected categories, the practical guidance is to maintain regular conversation with their prescribing clinicians about supply conditions in their specific medications. Several health systems have, in response to the persistent shortages, built better internal forecasting; conversations with the system's pharmacy operations can produce more accurate near-term supply expectations than the broader public guidance.

The clinician side

The clinician side of the shortage conversation has been the part that has changed most over the past several years. Substitution decisions that previously required case-by-case analysis are now governed by structured protocols at most large health systems; the protocols produce faster and more consistent decisions than the prior approach.

The longer view

The longer view is that the shortages will remain a recurring feature of the healthcare landscape for the foreseeable future. The structural reasons that produce them are slow to change, and the affected categories are too small a part of the broader pharmaceutical economy to attract the kind of policy attention that would meaningfully alter the underlying conditions.